Solvay launches hydrogen platform
Solvay’s polymer membranes technology will be a key element in hydrogen market
Brussels, January 13, 2021
Solvay has launched a hydrogen platform that will bring together all the innovative material and chemical solutions the Group has to offer to advance the emerging hydrogen economy. At the heart of the platform is Solvay’s membrane technology (ion conducting polymer), which constitutes a necessary component in the process of hydrogen production.
By creating this platform, Solvay is increasing its resources dedicated to this emerging market, including efforts in research and innovation. As from this year, Solvay is fully dedicating teams involving research, engineering, sales and marketing working together in crafting Solvay’s added value to the future hydrogen market.
Together with its membrane technology, under the brand Aquivion® that will be a key contributor to the electrolyser and fuel cells markets, Solvay also intends to bring other hydrogen applications and components to the market, such as hydrogen tanks.
“The hydrogen economy has taken-off, and with our new hydrogen platform, we are partnering with our customers in the electrolyser and fuel cells space to make it happen,” said Solvay CEO Ilham Kadri. “Green hydrogen will be one of the most competitive low carbon solutions for transportation applications in the near future and I’m proud that Solvay’s membrane technology will be a key element in the transition towards cleaner mobility, helping the fight against global climate change.”
As part of this commitment, Solvay has also joined the Hydrogen Council, a global CEO-led initiative that brings together leading companies with a united vision and long-term ambition for hydrogen to foster the clean energy transition. Solvay’s hydrogen platform is integral to the Group’s One Planet initiative, which includes ten measurable commitments to achieve the SDGs across three focus areas: climate, resources and better life.
Solvay has been researching and developing its ionomer technology for the past twenty years in preparation for the development of hydrogen technology. Solvay’s technology has demonstrated its value proposition with customers; the company has multiple qualifications underway with sizable sales potential in the next few years.
While lithium-ion batteries have emerged as the preferred solution to make the automotive sector more sustainable, this is not enough as they do not cover all needs related to the necessary decarbonization to make transportation truly sustainable. Hydrogen is poised to fill that gap.
Production of green hydrogen via water electrolysis is expected to reach more than 100GW of global capacity by 2030, while the global fleet of fuel cell electric vehicles - ranging from large passenger cars to heavy-duty commercial vehicles, trucks, buses and even trains - is forecasted to reach several million vehicles by 2030.
Clean hydrogen fuel is a key component of the EU's Green Deal, as it is a recognized technology needed to support ambitions towards an ecological and sustainable energy transition. Public support for hydrogen is increasing exponentially, with USD 10 billion of post-Covid19 stimulus being dedicated (mostly in Europe and APAC) to green hydrogen R&D and infrastructure deployment.
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
REPURCHASE OF SHARES20.1.2021 18:15:00 CET | Press release
REPURCHASE OF SHARES Amsterdam, the Netherlands - Flow Traders N.V. (“Flow Traders”) (Euronext: FLOW) has repurchased 62,790 of its own shares in the period from 14 January 2021 up to and including 20 January 2021 at an average price of €28.52. As announced on 11 November 2020, these repurchases are being made in order to satisfy the requirements of various employee incentive plans. The consideration of this purchase was €1.8 million. The total number of shares purchased under this programme to date is 799,922 shares at an average price of €26.90 for a total consideration of €21.5 million. 2,031,091 shares were held in treasury as at 20 January 2021. Contact Details Flow Traders N.V. Jonathan Berger / Investor Relations Officer Phone: +31 20 7996799 Email: firstname.lastname@example.org About Flow Traders Flow Traders is a leading global financial technology-enabled liquidity provider in financial products, historically specialized in Exchange Traded Products (ETPs), now expanding
KONNECT SELECTS SOLUTIONS 30 TO ROLL OUT ITS OFFER IN WESTERN EUROPE20.1.2021 18:00:00 CET | Press release
Solutions 30 (Euronext Paris: S30) has been selected by konnect, an entity of the Eutelsat Group (Euronext Paris: ETL), to roll out its new ultra high-speed satellite Internet access for the general public. As part of this partnership, Solutions 30 will carry out all installation services, allowing konnect to guarantee its customers a professional, uniform, and standardized installation in European countries where its offer is marketed. Europe’s leading provider of rapid-response multi-technology services, Solutions 30 performs more than 60,000 call-outs a day thanks to a team of 11,000 technicians and a particularly dense territorial network in Europe. For more than 15 years, the company has leveraged a unique software platform for team management and call-out optimization to provide customers with a standardized operating process that guarantees service quality and consistency. A significant part of Solutions 30’s business is in telecommunications, where it intervenes on behalf of th
Auction details government bonds20.1.2021 16:20:00 CET | Press release
Auction date January 27, 2021 Maturity date Loan ISIN code Coupon Issue volume, SEK million 2023-11-13 1057 SE0004869071 1.5% 1,5002031-05-12 1062 SE0013935319 0.125% 3,500 Settlement date January 29, 2021 Bids have to be entered by 11.00 on January 27, 2021 Bid only through dealers approved by the Swedish National Debt Office For more information, please contact: The funding desk + 46 8 613 4780 FO@riksgalden.se
SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING20.1.2021 16:20:00 CET | Press release
Bid date, 2021-01-22Bid Submission Date2021-01-22Bid times10.30-11.00 (CET/CEST) on the Bid dateOffered Amount50 billion SEKMaximum Permitted Bid Volume12.5 billion SEK from an individual bidderSettlement Date2021-01-26Minimum Permitted Bid Volume10 million SEK per bidFinal Repayment Date2025-01-27Maximum Allocation25 per cent of Offered AmountAllocation TimeNo later than 11.30 (CET/CEST) on the Bid dateRepayment Date2022-01-26Option Repayment Date 12023-01-26Option Repayment Date 22024-01-26Interest rateThe Riksbank´s applicable repo rateAdditional interest rate0.10 per centConfirmation of bids to email@example.com Stockholm, 2021-01-20 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes20.1.2021 16:07:55 CET | Press release
Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the US in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. The submission follows the application on 29 December 2020 for label extension to the European Medicines Agency (EMA). The submission is based on the results from the SUSTAIN FORTE trial, which included 961 people with type 2 diabetes in need of treatment intensification. In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c compared to semaglutide 1.0 mg. In the tria
ArcAroma AB: 210120 ArcAroma och OptiFreeze skapar tillsammans ett starkare bolag20.1.2021 16:00:00 CET | Pressemelding
Pressmeddelande 2021-01-20 ArcAroma och OptiFreeze skapar tillsammans ett starkare bolag Styrelserna i ArcAroma AB (publ) och OptiFreeze AB (publ) beslutade igår att föreslå ett samgående mellan bolagen genom fusion. Beslutet har tagits mot bakgrund av den marknadspotential och de synergieffekter som identifierats i samband med bolagens utökade samarbetsavtal, som tecknades i november 2020. ArcAroma och OptiFreeze har i olika omfattning samarbetat sedan grundandet av OptiFreeze 2011, där ArcAroma var en av grundarna till OptiFreeze. Sedan bolagens utökade samarbete inleddes i november 2020 har marknadsmöjligheter och synergier framstått som allt tydligare om bolagens resurser och tillväxtpotential kombineras. När fusionen är genomförd är målet att inleda processen för ett listbyte till Nasdaq Stockholm Small Cap. Storleken på det fusionerade bolaget skapar rätt förutsättningar för en kostnadseffektiv accelererad tillväxt som vilar på en unik teknologiplattform. Det nya bolagets kostnad
Equinor ASA: Early Warning Press Release20.1.2021 12:49:07 CET | Press release
Stavanger, Rogaland, Norway, January 20, 2021 – Equinor ASA ("Equinor") (OSE: EQNR, NYSE: EQNR) announces that on January 19, 2021 it disposed of its beneficial ownership of an aggregate of 100,000,000 common shares ("Common Shares") of Athabasca Oil Corporation ("Athabasca"), at a price of C$0.18 per Common Shares, for aggregate gross proceeds of C$18,000,000 (the "Transaction"), through the facilities of the Toronto Stock Exchange on a block trade basis. Immediately prior to the Transaction, Equinor beneficially owned and controlled a total of 100,000,000 Common Shares of Athabasca, representing approximately 18.8% of the issued and outstanding Common Shares of Athabasca. Immediately following the Transaction, Equinor no longer has beneficial ownership and control over any of the issued and outstanding Common Shares of Athabasca. As a result of the Transaction, Equinor's beneficial ownership of Common Shares of Athabasca has decreased to less than 10% of the issued and outstanding Co